AbbVie vs Medtronic stock
Side by side in plain words: who keeps more of its sales, grows faster, costs less and owes less.
AbbVie grows faster. Medtronic is more profitable, is cheaper for its profits and has less debt.
Side by side
| AbbVie | Medtronic | |
|---|---|---|
| $506 billion | $128 billion | |
| 6.9% | 13.2% | |
| +6.0% | +3.8% | |
| 119.7× | 26.6× | |
| 3.5 years | 2.7 years | |
| 12.0% | 7.2% | |
| 3.1% | 3.5% |
How we compare
Four contests with the same rules as each stock page: profit kept from sales (higher wins), yearly sales growth across the last reports, up to five years (higher wins), price per unit of yearly profit (lower P/E wins; a company without profit loses) and debt in years of earnings (lower wins). A winner is only named when both companies have the number.
More comparisons: AbbVie vs Merck & · AbbVie vs Merck KGaA · AbbVie vs Moderna · AbbVie vs Novo Nordisk · Medtronic vs Amgen · Medtronic vs Bristol-Myers Squibb · Medtronic vs Intuitive Surgical · Medtronic vs Johnson & Johnson

